This segment focuses on the research, development, and manufacturing of Heparin Active Pharmaceutical Ingredients (APIs) and their subsequent formulations. The R&D activities include process optimization for crude heparin extraction, purification, and modification to produce various heparin derivatives such as low molecular weight heparin (LMWH). Technologies employed involve chromatography, filtration, and chemical synthesis. The therapeutic area is primarily cardiovascular and cerebrovascular diseases, with products including heparin sodium injections, LMWH injections (enoxaparin, dalteparin, nadroparin), and their raw materials. The patient impact is significant, as these drugs are crucial for preventing and treating blood clots. Market positioning is strong in China, with a focus on high-quality, cost-effective heparin products. Future opportunities include expanding the product portfolio, entering new markets, and developing innovative delivery systems. Regulatory aspects involve compliance with Chinese and international GMP standards and obtaining necessary approvals. Partnerships with pharmaceutical companies for distribution and clinical trials are key to growth.